Combatting AntiMicrobial Resistance in Africa Using Data Science (CAMRA)
利用数据科学对抗非洲的抗菌素耐药性 (CAMRA)
基本信息
- 批准号:10316285
- 负责人:
- 金额:$ 114.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-15 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAfricaAfricanAminoglycosidesAmpicillin ResistanceAntibioticsAntimicrobial ResistanceArchivesAreaAwarenessBacteriaBacterial InfectionsBacterial ProteinsBioinformaticsBiomedical EngineeringBloodBlood CirculationCaringCase Fatality RatesCause of DeathChildChloramphenicolClinicalCollectionCommunitiesComparative StudyComplexCountryDangerousnessDataData ScienceDemographic and Health SurveysDiagnosticDiagnostic ServicesDiarrheaDisease OutbreaksEnrollmentEnterobacteriaceaeEtiologyEvaluationExtended-spectrum β-lactamaseGenomicsGenotypeGeographyGoalsGrowthHealthcareHigh PrevalenceHumanHuman DevelopmentHuman ResourcesIncubatorsIndividualInfectionKnowledgeLaboratoriesLive BirthMaternal MortalityMicrobeMicrobiologyMolecularMolecular EpidemiologyMorbidity - disease rateMulti-Drug ResistanceMultiple Bacterial Drug ResistanceNewborn InfantNigeriaNigerianPathway interactionsPeriodicityPharmacy facilityPhenotypePneumoniaPopulationPrevalencePrevention strategyProgram DevelopmentResearch ProposalsResourcesRwandaSalmonella typhiScientistScreening procedureSentinelSepsisSiteSputumStreamSyndromeTobramycinTrainingTreatment EfficacyTrimethoprim-SulfamethoxazoleUnited NationsUrineVeterinariansWarWomanage groupagedantimicrobialantimicrobial peptidebacterial resistancebactericidecarbapenem resistanceclinical careclinical epidemiologycomparativehealth care serviceindexinginflammatory markermortalitymultidisciplinarynovelpathogenic bacteriaportabilityprogramsresistance generesistant Klebsiella pneumoniaetransmission processtrend
项目摘要
Bacterial infections are highly prevalent and contribute significantly to morbidity and mortality
across all age-groups but because appropriate microbiologic diagnostic services are non-
existent or very limited, ascertaining the specific etiologic agents and the true prevalence of
antimicrobial resistance (AMR) is a major challenge in Africa, where objective data is limited.
Preliminary observations from Nigeria, the most populous country in Africa include the
following; a) High prevalence of Salmonella enterica serovar Typhi (S. Typhi) with 45%
prevalence of multidrug resistance, b) High prevalence of Extended Spectrum β-Lactamase-
producing Enterobacteriaceae (ESBL-E) blood stream infections, c) Maternal colonization by
ESBL-E in women at delivery is associated with high all-cause morbidity and mortality in their
newborn babies compared to ESBL-unexposed babies and d) Periodic outbreaks of
carbapenem-resistant Klebsiella pneumoniae sepsis in newborn units with case fatality rates as
high as 45%. We have preliminary molecular characterization of about 500 of the 2,750 diverse
bloodstream bacterial isolates in our collection. In addition, we have access to a collection of
over 2,500 clinical isolates of blood, sputum and urine from our sentinel laboratories in Nigeria
and Rwanda that are partially characterized. Our unique observations related to AMR genes
that we have identified in our archived isolates form the basis for this research proposal. Our
overall strategy in this application focuses on three thematic areas: 1). Comparative
phenotypic and genotypic studies of archived and contemporary clinical isolates to inform trends
in AMR and dynamics of transmission. 2) Incorporation of acute inflammatory markers of
serious bacterial infection and gene products from resistant bacteria into a portable screening
tool for clinical care and 3). Explore the potential benefit of an aminoglycoside (Tobramycin)
conjugated to an antimicrobial peptide for enhanced bactericidal activity against multi-drug
resistant enterobacteriales. We have assembled a multidisciplinary team of clinical and
molecular microbiologists, clinicians, biomedical engineers, environmental microbiologists,
veterinarians, and industrialists to implement this project in Nigeria, West Africa and also
Rwanda, East Africa to provide data with geographic representation for Africa. Upon successful
completion of this program, we would have utilized the data science platform for bacteria
genomics and antimicrobial resistance to raise awareness on the scope of AMR in Africa,
provide novel pathways for optimizing empiric use of antibiotics and trained a handful of young
African scientists in bacterial genomics and bioinformatics.
细菌感染是非常普遍的,并有助于显着的发病率和死亡率
所有年龄组,但由于适当的微生物学诊断服务是不,
存在或非常有限,确定具体的病原体和真正的患病率,
抗生素耐药性(AMR)是非洲的一个主要挑战,客观数据有限。
非洲人口最多的国家尼日利亚的初步观察结果包括:
a)伤寒沙门氏菌(S.伤寒)45%
多药耐药的流行率,B)超广谱β-内酰胺酶的高流行率-
产生肠杆菌科(ESBL-E)的血流感染,c)母体定植,
ESBL-E在分娩妇女中与高全因发病率和死亡率相关,
新生儿与未暴露于ESBL的婴儿相比,以及d)
新生儿病房中碳青霉烯类耐药肺炎克雷伯菌败血症的病死率
高达45%。我们对2,750种不同的病毒中的500种进行了初步的分子鉴定,
血液中的细菌分离物此外,我们还可以访问一系列
来自我们在尼日利亚的哨点实验室的超过2,500份血液、痰液和尿液临床分离物
和卢旺达的部分特征。我们对AMR基因的独特观察
我们在存档的分离株中鉴定出的基因构成了本研究提案的基础。我们
本申请的总体战略侧重于三个主题领域:1)。比较
存档和当代临床分离株的表型和基因型研究,以告知趋势
AMR和传播动力学。2)急性炎症标志物的掺入
严重的细菌感染和耐药菌的基因产物进入便携式筛查
临床护理工具; 3)。探索氨基糖苷类(妥布霉素)的潜在益处
与抗微生物肽缀合以增强对多种药物的杀菌活性
耐药肠杆菌我们组建了一个多学科的临床团队,
分子微生物学家,临床医生,生物医学工程师,环境微生物学家,
兽医和工业家在尼日利亚,西非实施这个项目,
卢旺达,东非提供非洲具有地域代表性的数据。一旦成功
完成这个项目后,我们将利用细菌的数据科学平台,
基因组学和抗生素耐药性,以提高人们对非洲AMR范围的认识,
为优化抗生素的经验性使用提供了新的途径,并培训了一些年轻人,
非洲细菌基因组学和生物信息学科学家。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Derrick E Fouts其他文献
Derrick E Fouts的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Derrick E Fouts', 18)}}的其他基金
Optimization, Manufacturing and Testing of a Lead Therapeutic Bacteriophage Cocktail for the Treatment of Antibiotic-Resistant Klebsiella pneumoniae Infections
用于治疗耐抗生素肺炎克雷伯菌感染的先导治疗噬菌体混合物的优化、制造和测试
- 批准号:
10674294 - 财政年份:2023
- 资助金额:
$ 114.59万 - 项目类别:
Combatting AntiMicrobial Resistance in Africa Using Data Science (CAMRA)
利用数据科学对抗非洲的抗菌素耐药性 (CAMRA)
- 批准号:
10490849 - 财政年份:2021
- 资助金额:
$ 114.59万 - 项目类别:
CK20-004, J. Craig Venter Insitute and Cleveland VA Prevention and Intervention Epicenter
CK20-004,J. Craig Venter 研究所和克利夫兰弗吉尼亚州预防和干预中心
- 批准号:
10649550 - 财政年份:2021
- 资助金额:
$ 114.59万 - 项目类别:
CK20-004, J. Craig Venter Insitute and Cleveland VA Prevention and Intervention Epicenter
CK20-004,J. Craig Venter 研究所和克利夫兰弗吉尼亚州预防和干预中心
- 批准号:
10466704 - 财政年份:2021
- 资助金额:
$ 114.59万 - 项目类别:
CK20-004, J. Craig Venter Insitute and Cleveland VA Prevention and Intervention Epicenter
CK20-004,J. Craig Venter 研究所和克利夫兰弗吉尼亚州预防和干预中心
- 批准号:
10402227 - 财政年份:2021
- 资助金额:
$ 114.59万 - 项目类别:
Combatting AntiMicrobial Resistance in Africa Using Data Science (CAMRA)
利用数据科学对抗非洲的抗菌素耐药性 (CAMRA)
- 批准号:
10655621 - 财政年份:2021
- 资助金额:
$ 114.59万 - 项目类别:
Microbiome as therapeutic target in alcoholic hepatitis
微生物组作为酒精性肝炎的治疗靶点
- 批准号:
9791138 - 财政年份:2018
- 资助金额:
$ 114.59万 - 项目类别:
Microbiome as therapeutic target in alcoholic hepatitis
微生物组作为酒精性肝炎的治疗靶点
- 批准号:
10427256 - 财政年份:2018
- 资助金额:
$ 114.59万 - 项目类别:
Microbiome as therapeutic target in alcoholic hepatitis
微生物组作为酒精性肝炎的治疗靶点
- 批准号:
10198649 - 财政年份:2018
- 资助金额:
$ 114.59万 - 项目类别:
Human Milk Oligosaccharides for Prevention of Alcohol-Associated Liver Disease
母乳低聚糖用于预防酒精相关性肝病
- 批准号:
10266673 - 财政年份:2018
- 资助金额:
$ 114.59万 - 项目类别:
相似海外基金
A mixed methods approach to address multi-level barriers to care for migratory men living with HIV in South Africa
采用混合方法解决照顾南非艾滋病毒携带者移民男性的多层次障碍
- 批准号:
10403224 - 财政年份:2022
- 资助金额:
$ 114.59万 - 项目类别:
Using the EPIC model to build transdisciplinary communities of practice that effectively address urban resilience in Africa and Asia
使用 EPIC 模型建立跨学科实践社区,有效解决非洲和亚洲的城市复原力问题
- 批准号:
2103692 - 财政年份:2022
- 资助金额:
$ 114.59万 - 项目类别:
Standard Grant
A mixed methods approach to address multi-level barriers to care for migratory men living with HIV in South Africa
采用混合方法解决照顾南非艾滋病毒携带者移民男性的多层次障碍
- 批准号:
10689689 - 财政年份:2022
- 资助金额:
$ 114.59万 - 项目类别:
Complex intervention to optimise adolescent BMI pre-conception to address the double burden of malnutrition: A RCT in rural and urban South Africa
优化青少年孕前体重指数以解决营养不良的双重负担的复杂干预措施:南非农村和城市的随机对照试验
- 批准号:
MR/V005790/1 - 财政年份:2021
- 资助金额:
$ 114.59万 - 项目类别:
Research Grant
Complex intervention to optimise adolescent BMI pre-conception to address the double burden of malnutrition: A RCT in rural and urban South Africa
优化青少年孕前体重指数以解决营养不良的双重负担的复杂干预措施:南非农村和城市的随机对照试验
- 批准号:
MR/V005790/2 - 财政年份:2021
- 资助金额:
$ 114.59万 - 项目类别:
Research Grant
An implementation science approach to address multi-level barriers to cancer screening among women living with HIV in South Africa
一种实施科学方法,以解决南非艾滋病毒感染妇女癌症筛查的多层次障碍
- 批准号:
10242935 - 财政年份:2020
- 资助金额:
$ 114.59万 - 项目类别:
A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East Africa
解决东非艾滋病毒流行的持续驱动因素的多部门战略
- 批准号:
10267216 - 财政年份:2020
- 资助金额:
$ 114.59万 - 项目类别:
A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East Africa
解决东非艾滋病毒流行的持续驱动因素的多部门战略
- 批准号:
10085144 - 财政年份:2020
- 资助金额:
$ 114.59万 - 项目类别:
A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East Africa
解决东非艾滋病毒流行的持续驱动因素的多部门战略
- 批准号:
10438844 - 财政年份:2020
- 资助金额:
$ 114.59万 - 项目类别:
Teaching empowerment: Grass-roots educators' strategies to address gender equity in the context of the HIV epidemic in South Africa
教学赋权:基层教育工作者在南非艾滋病毒流行背景下解决性别平等问题的战略
- 批准号:
218055 - 财政年份:2010
- 资助金额:
$ 114.59万 - 项目类别:
Studentship Programs